Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • GSK621: Selective AMPK Agonist for Metabolic Pathway & AM...

    2026-01-23

    GSK621: Selective AMPK Agonist for Metabolic Pathway & AML Research

    Executive Summary: GSK621 is a specific AMPK activator that induces robust phosphorylation of AMPKα at T172 and downstream effectors such as acetyl-CoA carboxylase (ACC) in cell-based and in vivo studies (APExBIO product page). It induces apoptosis in acute myeloid leukemia (AML) cells and reduces leukemia growth in xenograft mouse models at 30 mg/kg twice daily (Xiao et al., 2024). GSK621 inhibits mTORC1-dependent protein synthesis and promotes autophagy, fatty acid oxidation, and glucose uptake. Its solubility profile and workflow flexibility make it a reference tool for metabolic pathway and immunometabolic research. The compound is available from APExBIO as SKU B6020 for research use only.

    Biological Rationale

    AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine kinase that functions as a central energy sensor in eukaryotic cells. AMPK is activated by increases in the AMP/ATP ratio, typically under conditions of metabolic stress, hypoxia, or nutrient deprivation. Once activated, AMPK phosphorylates multiple downstream targets, including acetyl-CoA carboxylase (ACC) and Unc-51-like kinase 1 (ULK1), to shift cellular metabolism toward catabolism and energy conservation (Xiao et al., 2024). In tumor biology, AMPK activation has been implicated in suppression of anabolic pathways, induction of autophagy, and regulation of immune cell metabolism. Targeted activation of AMPK offers a mechanistic approach to modulate metabolic reprogramming in cancer and immune cells.

    Mechanism of Action of GSK621

    GSK621 is a selective and potent agonist of AMPK. It activates AMPK in a concentration-dependent manner with IC50 values of 13–30 µM across multiple cell lines (APExBIO). Upon administration, GSK621 promotes phosphorylation of AMPKα at threonine 172 (T172), a hallmark of AMPK activation. This leads to phosphorylation of ACC at serine 79 (S79), resulting in inhibition of fatty acid biosynthesis. GSK621 further induces phosphorylation of ULK1 at serine 555 (S555), promoting autophagy. AMPK activation by GSK621 suppresses mammalian target of rapamycin complex 1 (mTORC1), reducing protein synthesis and facilitating metabolic reprogramming. In AML models, these events culminate in apoptosis induction and decreased proliferation. The compound is cell-permeable, enabling modulation of AMPK signaling in diverse experimental contexts.

    Evidence & Benchmarks

    • GSK621 activates AMPK with IC50 values ranging from 13 to 30 µM in multiple cell lines (APExBIO).
    • Induces robust phosphorylation of AMPKα at T172 and ACC at S79 in AML cells and primary samples (Xiao et al., 2024).
    • Inhibits mTORC1-dependent protein synthesis by suppressing mTORC1 signaling (Xiao et al., 2024).
    • Promotes autophagy, fatty acid oxidation, and glycolysis in vitro (APExBIO).
    • In vivo, intraperitoneal dosing at 30 mg/kg twice daily significantly reduces leukemia burden and extends survival in MOLM-14 xenograft mice, with increased AMPK activity and ACC phosphorylation correlating with efficacy (Xiao et al., 2024).
    • GSK621 is insoluble in water/ethanol, but soluble in DMSO at ≥28.5 mg/mL, and stable for months below –20°C (APExBIO).

    This article extends previous reviews such as GSK621: Advanced AMPK Agonist for Metabolic Pathway Research by providing updated in vivo efficacy benchmarks and solubility/stability data. For a focused discussion on immunometabolic modulation, see GSK621: Advanced AMPK Agonist for Immunometabolic Modulation, to which this article adds translational benchmarks in AML. For a comparative mechanistic overview, GSK621: A Next-Generation AMPK Agonist for Metabolic Pathways details pathway mapping, while this article adds quantitative in vivo and workflow data.

    Applications, Limits & Misconceptions

    GSK621 is primarily used as a research tool for interrogating AMPK signaling, metabolic pathway modulation, and apoptosis in hematologic malignancies such as AML. Its cell-permeability and robust pharmacodynamic readouts make it suitable for both in vitro and in vivo studies. GSK621 has also been applied in metabolic reprogramming studies in immunology, including in tumor-associated macrophage models (Xiao et al., 2024).

    Common Pitfalls or Misconceptions

    • GSK621 is not effective in models lacking functional AMPK complexes; loss-of-function lines may not respond.
    • The compound is not water- or ethanol-soluble; improper dissolution can lead to precipitation and unreliable dosing.
    • GSK621 is not intended for diagnostic or therapeutic use in humans; it is strictly for research applications.
    • Some effects attributed to GSK621 may be indirect; always confirm AMPK pathway engagement by measuring phosphorylation of canonical substrates.
    • Stock solutions require storage below –20°C for long-term stability; repeated freeze-thaw cycles are discouraged.

    Workflow Integration & Parameters

    For optimal use, dissolve GSK621 in DMSO to a stock concentration of ≥28.5 mg/mL. For cell-based assays, final DMSO concentrations should not exceed 0.1–0.2%. For in vivo studies, GSK621 can be administered intraperitoneally at 30 mg/kg, twice daily, as validated in murine AML xenografts. Solubility can be enhanced by warming to 37°C or using an ultrasonic bath. Store crystalline powder at 2–8°C and stock solutions below –20°C. For best results, confirm phosphorylation of AMPKα (T172), ACC (S79), and ULK1 (S555) as pharmacodynamic markers. GSK621 is available as SKU B6020 from APExBIO.

    Conclusion & Outlook

    GSK621 is a rigorously benchmarked, cell-permeable AMPK agonist with robust efficacy in metabolic pathway research and acute myeloid leukemia models. Its capacity to activate AMPK, inhibit mTORC1, and induce apoptosis and autophagy makes it a reference tool for translational studies into metabolism and immunometabolism. Ongoing research will clarify its utility in additional cancer and immune contexts. APExBIO provides validated supply and workflow guidance for this specialized reagent.